These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9591708)

  • 1. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120.
    Cavacini LA; Samore MH; Gambertoglio J; Jackson B; Duval M; Wisnewski A; Hammer S; Koziel C; Trapnell C; Posner MR
    AIDS Res Hum Retroviruses; 1998 May; 14(7):545-50. PubMed ID: 9591708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.
    Posner MR; Cavacini LA; Emes CL; Power J; Byrn R
    J Acquir Immune Defic Syndr (1988); 1993 Jan; 6(1):7-14. PubMed ID: 8417177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.
    Posner MR; Elboim HS; Cannon T; Cavacini L; Hideshima T
    AIDS Res Hum Retroviruses; 1992 May; 8(5):553-8. PubMed ID: 1381201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.
    Posner MR; Hideshima T; Cannon T; Mukherjee M; Mayer KH; Byrn RA
    J Immunol; 1991 Jun; 146(12):4325-32. PubMed ID: 1710248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression.
    Cavacini LA; Emes CL; Power J; Underdahl J; Goldstein R; Mayer K; Posner MR
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1093-102. PubMed ID: 7692037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding.
    Berkower I; Patel C; Ni Y; Virnik K; Xiang Z; Spadaccini A
    Virology; 2008 Aug; 377(2):330-8. PubMed ID: 18519142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.
    Cavacini LA; Emes CL; Power J; Desharnais FD; Duval M; Montefiori D; Posner MR
    J Immunol; 1995 Oct; 155(7):3638-44. PubMed ID: 7561063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys.
    Cavacini LA; Power J; Emes CL; Mace K; Treacy G; Posner MR
    J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):251-6. PubMed ID: 8061897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.
    Thali M; Olshevsky U; Furman C; Gabuzda D; Posner M; Sodroski J
    J Virol; 1991 Nov; 65(11):6188-93. PubMed ID: 1717717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.
    Wilkinson RA; Piscitelli C; Teintze M; Cavacini LA; Posner MR; Lawrence CM
    J Virol; 2005 Oct; 79(20):13060-9. PubMed ID: 16189008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization.
    Cavacini LA; Emes CL; Power J; Duval M; Posner MR
    J Immunol; 1994 Mar; 152(5):2538-45. PubMed ID: 7510748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells.
    Clayton R; Ohagen A; Goethals O; Smets A; Van Loock M; Michiels L; Kennedy-Johnston E; Cunningham M; Jiang H; Bola S; Gutshall L; Gunn G; Del Vecchio A; Sarisky R; Hallenberger S; Hertogs K
    J Virol Methods; 2007 Jan; 139(1):17-23. PubMed ID: 17034868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.
    Bagley J; Dillon PJ; Rosen C; Robinson J; Sodroski J; Marasco WA
    Mol Immunol; 1994 Oct; 31(15):1149-60. PubMed ID: 7935503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two new human monoclonal antibodies against HIV type 1 glycoprotein 120: characterization and neutralizing activities against HIV type 1 strains.
    Février M; Boudet F; Deslandres A; Theze J
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):491-500. PubMed ID: 7543271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.
    Chamat S; Nara P; Berquist L; Whalley A; Morrow WJ; Köhler H; Kang CY
    J Immunol; 1992 Jul; 149(2):649-54. PubMed ID: 1378074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.